O
Oramed Pharmaceuticals Inc. (ORMP)
NCM – Real Time Price. Currency in USD
4.45
-0.17 (-3.68%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
4.45
-0.17 (-3.68%)
At close: May 12, 2026, 4:00 PM EDT
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
| Name | Position |
|---|---|
| Dr. Miriam Kidron Ph.D. | Chief Scientific Officer & Director |
| Mr. Avraham Gabay | CFO, Treasurer & Secretary |
| Mr. Joshua Hexter | Chief Operating & Business Officer |
| Mr. Nadav Kidron Esq. | President, CEO & Executive Chairman |
| Date | Type | Document |
|---|---|---|
| 2026-03-31 | 8-K | ea0284244-8k_oramed.htm |
| 2026-03-26 | 10-K | ea0282618-10k_oramed.htm |
| 2026-02-20 | 8-K | ormp-20260219.htm |
| 2026-01-14 | 8-K | ea0272889-8k_oramed.htm |
| 2026-01-07 | 8-K | ea0271929-8k_oramed.htm |
| 2025-12-31 | 8-K | ea0271432-8k_oramed.htm |
| 2025-11-17 | 8-A12B | ea0265959-8a12b_oramed.htm |
| 2025-11-13 | 10-Q | ea0264871-10q_oramed.htm |
| 2025-10-24 | 8-K | ea0262319-8k_oramed.htm |
| 2025-10-06 | 8-K | ea0260371-8k_oramed.htm |